Synthesis of 4'α-C Phenyl-Branched Carbocyclic Nucleoside Using Ring-Closing Metathesis

Joon Hee Hong^{*} and Ok Hyun Ko

College of Pharmacy, Chosun University, Gwangju 501-759, Korea Received May 28, 2003

An efficient synthetic route for preparing novel $4'\alpha$ -*C* phenyl branched carbocyclic nucleoside is described. The installation of phenyl group at the 4'-position of carbocyclic nucleoside was successfully accomplished via a sequential [3,3]-sigmatropic rearrangement and ring-closing metathesis (RCM) beginning from simple ketone such as 2-hydroxy acetophenone.

Key Words : Carbocyclic nucleoside, Antiviral agents, [3,3]-Sigmatropic rearrangement, Ring-closing metathesis


Introduction

Carbocyclic nucleosides are a group of compounds that are structurally similar to natural nucleosides where the furanose oxygen is replaced by a methylene group. The replacement of the furanose ring oxygen by carbon is of particular interest because the resulting carbocyclic nucleosides possess a greater metabolic stability to phosphorylase,¹ which cleaves the glycosidic bond of nucleosides. Since the cyclopentane ring of carbocyclic nucleosides can emulate the furanose moiety, a number of these compounds exhibit interesting biological activities, particularly in the areas of antiviral and anticancer chemotherapy. The recent discovery of abacavir² as an anti-HIV agent has given a strong impetus to the search of novel nucleosides in this class of compounds.

Recently, several branched-nucleoside³ have been synthesized and evaluated as potent antitumor or antiviral agents. Among them, $4'\alpha$ -*C*-ethenyl,⁴ $4'\alpha$ -*C*-ethynyl⁵ and $4'\alpha$ -*C*cyano⁶ nucleosides, which have an additional double or triple bond at the 4'-position, were reported to exhibit potent antiviral and antitumor activities.

Encouraged by these interesting structures and antiviral activities, novel class of nucleoside comprising branched carbocyclic nucleosides with an additional phenyl group at 4'-position was synthesized (Figure 1).

It is well known that the [3,3]-sigmatropic rearrangement,⁷



*Corresponding author: Tel.: +82-62-230-6378; Fax: +82-62-222-5414; E-mail: hongjh@mail.chosun.ac.kr


RCM⁸ and Pd(0) catalyzed allylic alkylation⁹ have been employed widely in synthetic organic chemistry. A very convenient and general synthetic procedure for nucleosides using these procedures is described in this paper.

Results and Discussion

Although the synthetic methods of $4'\alpha$ -*C* alkyl branched furanose¹⁰ and carbocyclic nucleosides¹¹ have been reported, the branches were limited to only alkyl groups (CH₃, C₉H₁₉, Benzyl) with use of nucleophilic alkyl substitution reactions. Thus far, no synthetic example of 4'-phenyl branched nucleosides has been reported in the literature. The dearth of examples may be due to the synthetic difficulties for elaborating a necessary quaternary carbon containing phenyl group. As shown in Scheme 1, it was envisioned that the ring-closing metathesis of proper diolefin **7**, which could be readily synthesized *via* a sequential [3,3]-sigmatropic rearrangement and carbonyl addition starting from a simple acyclic precursor, the 2-hydroxy ketone derivative **1**, would produce phenyl branched cyclopentene **8** as the key intermediates.

The protection of the hydroxyl of commercially available starting material **1** with TBDMSCl followed by the Horner-Wadsworth-Emmons (HWE) reaction¹² provided the α,β -unsaturated ethyl ester **3** as *cis/trans* isomeric mixtures. It was unnecessary to separate these isomers, because they were merged into one isomer in subsequent reaction. Ester **3** was reduced to the allylic alcohols **4** using diisobutyl-aluminum hydride (DIBALH) in high yield, which were subjected to a normal Johnson's orthoester Claisen rearrangement⁷ using triethyl orthoacetate to give γ,δ -unsaturated ester **5** in 81% yield. The slow addition of DIBALH to a solution of the esters **5** in toluene at -78 °C furnished the desired aldehyde **6**, which was subjected to carbonyl addition by CH₂=CHMgBr to yield the olefin **7** as inseparable diastereomeric mixtures.

Without separation, each diolefin **7**, was subjected to the standard ring-closing metathesis⁸ conditions using [benzyl-idene-bis(tricyclohexylphosphine)-dichlororuthenium] to



Scheme 1. Reagents: a) TBDMSCI, CH₂Cl₂, imidazole, 0 °C, 5 h; b) Triethylphosphonoacetate, NaH, THF, rt, 1 h; c) DIBALH, CH₂Cl₂, -20 °C, 3 h; d) Triethylorthoacetate, propionic acid, overnight, 130-135 °C; e) DIBALH, toluene, -78 °C, 30 min.; f) CH₂=CHMgBr, THF, -78 °C, 2 h; g) Cl₂(Cy₃P)₂RuCHC₆H₅, CH₂Cl₂, reflux, overnight; h) ClCO₂Et, pyridine, DMAP, rt, 4 h; i) adenine, Pd₂(dba)₃·CHCl₃, P(O-*i*-Pr)₃, NaH, THF/DMSO, reflux, overnight; j) TBAF, THF, rt, 5 h.

provide the cyclopentenols 8 and 9, respectively. The stereochemical assignments were made on the basis of NOE experiments. On irradiation of C₁-H, NOE was observed at the methylene protons of the hydroxymethyl group of 9, but not at the methylene protons those of 8.

In order to couple the cyclopentenol with the adenine base using a routine nucleophilic substitution type reaction, the α isomers 9 was subjected to a mesylation reaction (MsCl, TEA, CH₂Cl₂).¹³ Unexpectedly, the reaction had a very low vield (10-20%) and was irreproducible. Therefore, our attention was turned to a Trost protocol.9 Palladium(0)-catalyzed reactions have played the central role in allylic functionalization. This methodology has been successfully applied to synthesizing the desired nucleosides. The cyclopentenol 8 was activated to 10 using ethyl chloroformate in a high yield (81%), which was coupled with an adenine anion generated by NaH/DMSO using the well-known coupling catalyst [tris(dibenzylidene-acetone)-dipalladium(0)-chloroform] adduct to give 11. The required stereochemistry of nucleoside 11 was successfully controlled from the β -configuration of 10 via Pd(0) catalyzed π -allyl complex mechanism.⁹ Although a small amount of the N7-regioisomer¹⁴ (<7%) was observed, the compound 11 and its N7-isomer could be easily separated. The desilylation of 11 was performed by a treatment with tetrabutylammonium fluoride (TBAF) to give the final nucleoside 12 in a 95% yield.

Based on extensive literature searching, the compound 12 appears to be a novel nucleoside. Antiviral evaluations against various viruses such as HIV-1, HSV-1, HSV-2 and HCMV were performed. However, it did not show any significant activity or cytotoxicity up to $100 \ \mu$ M.

In summary, a short and concise synthetic method for synthesizing $4'\alpha$ -*C* phenyl branched carbocyclic nucleosides from a simple α -hydroxy ketone derivative was developed. Our procedure highlights the simplicity and efficiency in the installation of phenyl branch at cyclopentene ring systems.

On the basis of this strategy, the enantiomeric syntheses of branched nucleosides with different nucleobases and substituents are in progress.

Experimental Section

All chemicals were reagent grade and were used as purchased. All moisture-sensitive reactions were performed in an inert atmosphere of either N_2 or Ar using distilled dry solvents. The elemental analyses were performed by Elemental Analyzer System (Profile HV-3). NMR spectra were recorded on a bruker 300 Fourier transform spectrometer.

2-(t-Butyldimethylsilyloxy)-acetophenone (2): TBDMSCl (22.4 g, 0.15 mol) was added slowly at 0 °C to a solution of 2-hydroxy acetophenone 1 (18.5 g, 0.135 mol) and imidazole (13.5 g, 0.203 mol) in CH₂Cl₂ (300 mL), and stirred for 5 h at the same temperature. The solvent was evaporated under a reduced pressure. The residue was extracted twice with diethyl ether and water. The combined organic layer was dried over anhydrous MgSO₄, filtered, and concentrated under a reduced pressure. The residue was purified by silica gel column chromatography (EtOAc/hexane, 1:10) to give compound 2 (32.5 g, 90%) as a colorless oil: ¹H NMR (CDCl₃, 300 MHz) δ 7.80 (d, J = 7.2 Hz, 2H), 7.46-7.30 (m, 3H), 4.79 (s, 2H), 0.80 (s, 9H), -0.01 (s, 6H); ¹³C NMR $(CDCl_3)$ δ 197.42, 134.85, 133.22, 128.56, 127.83, 67.40, 25.78, 18.44, -5.36; Anal calc for C₁₄H₂₂O₂Si: C, 67.15; H, 8.86. Found: C. 66.97: H. 8.65.

(E) and (Z)-4-(*t*-Butyldimethylsilyloxy)-3-phenyl-but-2-enoic acid ethyl ester (3): To a suspension of sodium hydride (60% in mineral oil, 0.74 g, 18.5 mmol) in distilled THF at 0 °C, triethyl phosphonoacetate (2.81 mL, 18.5 mmol) was added drop wise and with constant stirring at room temperature for 1 h. The ketone 2 (4.6 g, 18.5 mmol) was added to this mixture and stirred for 1 h. The solution was neutralized with AcOH, and extracted with EtOAc. The organic layer was washed with brine and dried over anhydrous MgSO₄, filtered and evaporated. The residue was purified by silica gel column chromatography (EtOAc/hexane, 1 : 15) to give **3** (4.9 g, 83%) as a colorless oil: ¹H NMR (CDCl₃, 300 MHz) as mixture δ 7.39-7.04 (m, 5H), 6.09, 5.93 (dt, *J* = 1.3, 1.8 Hz, 1H), 5.08, 4.23 (dd, *J* = 0.9, 2.1 Hz, 2H), 3.90 (dq, *J* = 6.9, 6.9 Hz, 2H), 1.20, 0.95 (dt, *J* = 6.9, 6.9 Hz, 3H), 0.84, 0.65 (s, s, 9H), 0.02, -0.10 (s, s, 6H); Anal calc for C₁₈H₂₈O₃Si: C, 67.46; H, 8.81. Found: C, 67.66; H, 8.95.

(E) and (Z)-4-(*t*-Butyldimethylsilyloxy)-3-methyl-but-2-en-1-ol (4): To a solution of 3 (8.9 g, 27.9 mmol) in CH₂Cl₂ (300 mL), DIBALH (58.55 mL, 1.0 M solution in hexane) was added slowly at -20 °C, and stirred for 1 h at the same temperature. To the resulting mixture, methanol (50 mL) was added. The mixture was stirred at room temperature for 3 h, and the resulting solid was filtered through a Celite pad. The filtrate was concentrated under vacuum and the residue was purified by silica gel column chromatography (EtOAc/hexane, 1 : 5) to give alcohol 4 (6.4 g, 83%) as a colorless oil: ¹H NMR (CDCl₃, 300 MHz) as mixture δ 7.32-7.07 (m, 5H), 5.99, 5.91 (dt, *J* = 6.6, 6.6 Hz, 1H), 4.31 (d, *J* = 6.6 Hz, 2H), 4.27 (s, 2H), 0.85, 0.81 (s, s, 9H), 0.02 (m, 6H); Anal calc for C₁₆H₂₆O₂Si: C, 69.01; H, 9.41. Found: C, 69.18; H, 9.26.

(±)-3-(t-Butyldimethylsilyloxymethyl)-3-phenyl-pent-4enoic acid ethyl ester (5): A solution of allylic alcohol 4 (19.3 g, 69.32 mmol) in triethyl orthoacetate (300 mL) and 0.9 mL of propionic acid was heated at 130-135 °C overnight with stirring to allow for the removal of ethanol. The excess of triethyl orthoacetate was removed by distillation and the residue was purified by silica gel column chromatography (EtOAc/hexane, 1:15) to give 5 (19.6 g, 81%) as a colorless oil: ¹H NMR (CDCl₃, 300 MHz) δ 7.36-7.25 (m, 5H), 6.26 (dd, J = 18.0, 11.1 Hz, 1H), 5.31 (dd, J = 11.4, 1.2 Hz, 1H), 5.16 (dd, J = 17.7, 0.6 Hz, 1H), 4.10-3.99 (m, 4H), 3.00 (s, 2H), 1.18 (t, J = 6.9 Hz, 3H), 0.99 (s, 9H), 0.02 (two s, 6H); ¹³C NMR (CDCl₃) δ 171.51, 143.17, 142.33, 127.82, 127.34, 126.30, 114.34, 67.73, 59.94, 48.70, 39.74, 25.76, 18.19, 14.07, -5.71; Anal calc for C₂₀H₃₂O₃Si: C, 68.92; H, 9.25. Found: C, 68.69; H, 9.05.

(±)-3-(*t*-Butyldimethylsilyloxymethyl)-3-phenyl-pent-4enal (6): To a solution of **5** (6.7 g, 19.2 mmol) in toluene (200 mL), DIBALH (14.1 mL, 1.5 M solution in toluene) was added slowly at -78 °C, and stirred for 30 min. at the same temperature. To the mixture, methanol (50 mL) was added. The mixture was stirred at room temperature for 2 h, and the resulting solid was filtered through a Celite pad. The filtrate was concentrated under vacuum and the residue was purified by silica gel column chromatography (EtOAc/ hexane, 1 : 15) to give **6** (4.4 g, 76%) as a colorless oil: ¹H NMR (CDCl₃, 300 MHz) δ 9.63 (s, 1H), 7.34-7.26 (m, 5H), 6.09 (dd, *J* = 17.7, 11.1 Hz, 1H), 5.34 (d, *J* = 11.1 Hz, 1H), 5.16 (d, *J* = 17.4 Hz, 1H), 3.86 (s, 2H), 2.97 (dq, *J* = 16.2, 3.0), 0.88 (s, 9H), -0.01 (s, 6H); ¹³C NMR (CDCl₃) δ 202.86, 142.38, 141.49, 128.38, 127.33, 126.83, 115.70, 69.28, 49.01, 25.76, 18.19, -5.74; Anal calc for C₁₈H₂₈O₂Si: C, 71.00; H, 9.27. Found: C, 71.34; H, 9.15.

(±)-(*3R* and *3S*,*5S*)-*5*-(*t*-Butyldimethylsilyloxymethyl)-5-phenyl-hepta-1,6-dien-3-ol (7): To a cooled (-78 °C) solution of **6** (7.0 g, 23.1 mmol) in dry THF (120 mL) vinylmagnesium bromide (27.7 mL, 1.0 M solution in THF) was added slowly. After 2 h, a saturated NH₄Cl solution (23 mL) was added, and the reaction mixture was warmed slowly to room temperature. The mixture was extracted with EtOAc (2×150 mL). The combined organic layer was dried over MgSO₄, filtered, and evaporated. The residue was purified by silica gel column chromatography (EtOAc/hexane, 1 : 10) to give **7** (6.4 g, 84%) as a colorless oil: ¹H NMR (CDCl₃, 300 MHz) δ 7.36-7.21 (m, 5H), 6.02-5.96 (m, 2H), 5.21-4.96 (m, 4H), 4.11-3.89 (m, 2H), 2.21-2.07 (m, 2H), 0.88 (m, 9H), 0.04 (m, 6H); Anal calc for C₂₀H₃₂O₂Si: C, 72.23; H, 9.70. Found: C, 72.31; H, 9.88.

(±)-(1*R*,4*S*)-4-(*t*-Butyldimethylsilyloxymethyl)-4-phenylcyclopent-2-enol (8); and (±)-(1S,4S)-4-(t-Butyldimethylsilyloxymethyl)-4-phenyl-cyclopent-2-enol (9): To a solution of 7 (3.1 g, 9.24 mmol) in dry CH₂Cl₂ (20 mL) Grubbs catalyst (0.76 g 0.92 mmol) in dry CH₂Cl₂ (10 mL) was added slowly over a 10-minute period under a N₂ atmosphere. The reaction mixture was refluxed overnight, and cooled to room temperature. The mixture was concentrated under vacuum, and the residue was purified by silica gel column chromatography (EtOAc/hexane, 1:5) to give the cyclopentenols, 8 (1.32 g, 47%) and 9 (1.3 g, 46%), as colorless oils, respectively. Compound 8: ¹H NMR (CDCl₃, 300 MHz) δ 7.28-7.12 (m, 5H), 6.03-5.97 (m, 2H), 4.60-4.53 (m, 1H), 3.65 (d, J = 9.6 Hz, 1H), 3.50 (d, J = 9.6 Hz, 1H), 2.33 (dd, J =13.8, 6.9 Hz, 1H), 2.12 (dd, J = 8.1, 6.9 Hz, 1H), 0.81 (s, 9H), -0.01 (s, 6H): ¹³C NMR (CDCl₃) δ 145.04, 136.44, 135.53, 128.46, 126.61, 75.62, 69.77, 58.70, 45.73, 26.00, 18.62, -5.41; Anal calc for C₁₈H₂₈O₂Si: C, 71.00; H, 9.27. Found: C, 70.73; H, 9.08. Compound 9: ¹H NMR (CDCl₃, 300 MHz) δ 7.24-7.19 (m, 5H), 6.12 (d, J = 4.8 Hz, 1H), 5.93 (dd, J = 6.0, 2.1 Hz, 1H), 4.87 (s, 1H), 3.55 (s, 2H), 2.70 (dd, J = 13.2, 7.2 Hz, 1H), 1.83 (dd, J = 18.0, 4.8 Hz, 1H), 0.75 (s, 9H), -0.13, -0.15 (s, s, 6H): ¹³C NMR (CDCl₃) δ 144.98, 135.74, 135.03, 127.86, 125.51, 75.02, 68.12, 57.65, 43.23, 25.78, 18.14, -5.43; Anal calc for C₁₈H₂₈O₂Si: C, 71.00; H, 9.27. Found: C, 71.19; H, 9.11.

(±)-(1*R*,4*S*)-1-Ethoxy carbonyloxy-4-(*t*-butyldimethylsilyloxymethyl)-4-phenyl-cyclopent-2-ene (10): To a solution of **8** (4.4 g, 14.43 mmol) in anhydrous pyridine (50 mL) ethyl chloroformate (2.76 mL, 28.87 mmol) and DMAP (0.17 g, 1.4 mmol) was added. The reaction mixture was stirred for 4 h at room temperature. The reaction mixture was quenched with a saturated NaHCO₃ solution (2 mL) and concentrated under vacuum. The residue was extracted with EtOAc, dried over MgSO₄, filtered, and concentrated. The residue was purified by silica gel column chromatography (EtOAc/hexane, 1 : 10) to give **10** (4.4 g, 81%) as a colorless syrup: ¹H NMR (CDCl₃, 300 MHz) δ 7.41-7.31 (m, 5H), 6.56 (d, *J* = 5.7 Hz, 1H), 6.15 (dd, *J* = 6.0, 2.4 Hz, 1H), 5.72 (br d, 1H), 4.36 (q, *J* = 7.5 Hz, 2H), 3.93 (d, *J* = 9.3 Hz, 1H), 3.87 (d, J = 9.3 Hz, 1H), 2.64 (dd, J = 14.1, 7.2 Hz, 1H), 2.39 (dd, J = 14.1, 3.3 Hz, 1H), 1.44 (t, J = 7.2 Hz, 3H), 0.97 (s, 9H), 0.04 (s, 6H): ¹³C NMR (CDCl₃) δ 154.99, 145.24, 142.32, 129.57, 128.06, 126.89, 126.22, 82.88, 71.24, 63.78, 58.61, 40.97, 25.77, 18.20, 14.31, -5.61; Anal calc for C₂₁H₃₂O₄Si: C, 66.98; H, 8.57. Found: C, 66.70; H, 8.60.

 (\pm) -(1'R,4'S)-9-[4-(t-Butyldimethylsilyloxymethyl)-4phenyl-cyclopent-2-en-1-yl] adenine (11): To a pure NaH (23.4 mg, 0.98 mmol) in anhydrous DMSO (3.4 mL) adenine (134 mg, 0.98 mmol) was added. The reaction mixture was stirred for 30 min at 50-55 °C and cooled to room temperature. Simultaneously, P(O-i-Pr)₃ (0.096 mL, 0.22 mmol) was added to a solution of Pd₂(dba)₃·CHCl₃ (4.6 mg, 2.5 mmol) in anhydrous THF (3.0 mL), which was stirred for 40 min. To the adenine solution of DMSO, a catalyst solution of THF and 10 (331 mg, 0.88 mmol) dissolved in anhydrous THF (3 mL) was added slowly. The reaction mixture was stirred overnight at a refluxing temperature and quenched with water (2 mL). The reaction solvent was removed under reduced pressure. The residue was purified by silica gel column chromatography (MeOH/ CH₂Cl₂, 1 : 15) to give **11** (207 mg, 56%) as a white solid: mp 189-192 °C; UV (MeOH) λ_{max} 261 nm ¹H NMR (CDCl₃, 300 MHz) δ 8.34 (s, 1H), 8.00 (s, 1H), 7.36-7.22 (m, 5H), 6.43 (dd, J = 5.4, 2.1 Hz, 1H), 6.02 (br s, 3H), 5.79 (t, J = 6.6 Hz, 1H), 3.84 (d, J = 9.3 Hz, 1H), 3.79 (d, J = 9.3 Hz, 1H), 2.91 (dd, J = 13.5, 8.4 Hz, 1H), 2.43 (dd, J = 13.5, 6.6 Hz, 1H), 0.86 (s, 9H), 0.01 (s, 6H); 13 C NMR (CDCl₃) δ 155.57, 152.84, 149.91, 144.49, 141.75, 138.87, 129.75, 128.46, 127.16, 119.71, 69.96, 59.29, 42.70, 25.94, 18.45, -5.37; Anal calc for C₂₃H₃₁N₅OSi: C, 65.52; H, 7.41; N, 16.61. Found: C, 65.77; H, 7.54; N, 16.65.

(±)-(1'R,4'R)-9-[4-(Hydroxymethyl)-4-phenyl-cyclopent-2-en-1-yl] adenine (12): To a solution of 11 (291 mg, 0.69 mmol) in THF (10 mL), TBAF (1.04 mL, 1.0 M solution in THF) at 0 °C was added. The mixture was stirred at room temperature for 5 h, and concentrated. The residue was purified by silica gel column chromatography (MeOH/ CH₂Cl₂, 1 : 5) to give **12** (201 mg, 95%) as a white solid: mp 218-220 °C; UV (H₂O) λ_{max} 261 nm; ¹H NMR (DMSO- d_6 , 300 MHz) δ 8.12 (s, 1H), 8.11 (s, 1H), 7.33-7.29 (m, 5H), 7.21 (br s, 2H), 6.44 (dd, J = 5.4, 2.1 Hz, 1H), 6.08 (dd, J =6.0, 2.4 Hz, 1H), 5.60 (dd, J = 8.1, 6.0 Hz, 1H), 5.01 (t, J = 5.4 Hz, 1H), 3.68-3.56 (m, 2H), 2.70 (dd, *J* = 13.8, 8.4 Hz, 1H), 2.35 (dd, J = 13.5, 6.0 Hz, 1H); ¹³C NMR (DMSO- d_6) δ 155.95, 152.25, 149.22, 145.40, 141.06, 138.85, 129.68, 128.19, 126.56, 126.15, 68.47, 59.14, 41.98; Anal calc for C₁₇H₁₇N₅O: C, 66.43; H, 5.58; N, 22.79. Found: C, 66.70; H, 5.72; N, 22.98.

Acknowledgements. We thank Dr. C.-K Lee (Korea Research Institute of Chemical Technology) for antiviral assays.

References

1. Stoeckler, J. D.; Cambor, C.; Parks, R. E., Jr. Biochemistry 1980,

19, 102.

- (a) Daluge, S. M.; Good, S. S.; Faletto, M. B.; Miller, W. H.; St Clair, M. H.; Boone, L. R.; Tisdale, M.; Parry, N. R.; Reardon, J. E.; Dornsife, R. E.; Averett, D. R.; Krenitsky, T. A. Antimicrob. Agents Chemother. 1997, 41, 1082; (b) Dobkin, J. F. Infect. Med. 1999, 17, 625.
- 3. (a) Maag, H.; Rydzewski, R. M.; McRoberts, M. J.; Verheyden, J .P. H.; Prisbe, E. J. J. Med. Chem. 1992, 35, 1440; (b) Chen, M. S.; Suttmann, R. T.; Papp, E.; Cannon, P. D.; McRobert, M. J.; Bach, C.; Copeland, W. C.; Wang, T. S. F. Biochemistry 1993, 32, 6002; (c) Maag, H.; Nelson, J. T.; Rios-Steiner, J. L.; Prisbe, E. J. J. Med. Chem. 1994, 37, 431; (d) Maguire, A. R.; Meng, W. G.; Roberts, S. M.; Willetts, A. J. J. Chem. Soc., Perkin Trans. 1 1993, 1795; (e) Jenkins, I. D.; Verheyden, J. P. H.; Moffatt, J. G. J. Am. Chem. Soc. 1976, 98, 3346; (f) Guillerm, D.; Muzard, M.; Allart, B.; Guillerm, G. Bioorg. Med. Chem. Lett. 1995, 5, 1455; (g) Crich, D.; Hao, X. J. Org. Chem. 1999, 64, 4016; (h) Crich, D.; Hao, X. J. Org. Chem. 1998, 63, 3796; (i) Jung, M. E.; Toyota, A. J. Org. Chem. 2001, 66, 2624; (j) Brown, B.; Hegedus, L .S. J. Org. Chem. 2000, 65, 1865; (k) Hegedus, L. S.; Geisler, L.; Riches, A. G.; Salman, S. S.; Umbricht, G. J. Org. Chem. 2002, 67, 7649; (1) Hegedus, L. S.; Hervert, K. L.; Matsui, S. J. Org. Chem. 2002, 67, 4076.
- Sugimoto, I.; Shuto, S.; Mori, S.; Shigeta, S.; Matuda, A. Bioorg. Med. Chem. Lett. 1999, 9, 385.
- (a) Nomura, M.; Shuto, S.; Tanaka, M.; Sasaki, T.; Mori, S.; Shigeta, S.; Matsuda, A. *J. Med. Chem.* **1999**, *42*, 2901; (b) Ohrui, H.; Kohgo, S.; Kitano, K.; Sakata, S.; Kodama, E.; Yoshimura, K.; Matsuoka, M.; Shigeta, S.; Mitsuya, H. *J. Med. Chem.* **2000**, *43*, 4516.
- O'Yang, C.; Wu, H. Y.; Fraser-Smith, E. B.; Walker, K. A. M. Tetrahedron Lett. 1992, 33, 37.
- For selected references for nucleosides: (a) Ko, O. H.; Hong, J. H. *Tetrahedron Lett.* **2002**, *43*, 6399; (b) Hong, J. H.; Gao, M. Y.; Choi, Y.; Cheng, Y.-C.; Schinazi, R. F.; Chu, C. K. *Carbohydrate Res.* **2000**, *328*, 37; (c) Hong, J. H.; Gao, M. Y.; Chu, C. K. *Tetrahedron Lett.* **1999**, *40*, 231; (d) Hong, J. H.; Lee, K.; Choi, Y.; Chu, C. K. *Tetrahedron Lett.* **1988**, *39*, 3443.
- For selected references for nucleosides: (a) Hong, J. H.; Shim, M. J.; Ro, B. O.; Ko, O. H. J. Org. Chem. 2002, 67, 6387; (b) Ewing, D.; Glacon, V.; Mackenzie, G.; Postel, D.; Len, C. Tetrahedron Lett. 2002, 43, 3503; (c) Gurjar, M. K.; Maheshwar, K. J. Org. Chem. 2001, 66, 7552; (d) Crimmins, M. T.; King, B. W.; Zuercher, W. J.; Choy, A. L. J. Org. Chem. 2000, 65, 8499.
- For selected references for nucleosides: (a) Trost, B. M.; Kallander, L. S. J. Org. Chem. **1999**, 64, 5427; (b) Trost, B. M.; Shi, Z. J. Am. Chem. Soc. **1996**, 118, 3037; (c) Deardorff, D. R.; Savin, K. A.; Justman, C. J.; Karanjawala, Z. E.; Sheppeck, II, J. E.; Hager, D. C.; Aydin, N. J. Org. Chem. **1996**, 61, 3616; (d) Nokami, J.; Matsuura, H.; Nakasima, K.; Shibata, S. Chemistry Lett. **1994**, 1071; (e) Evans, C. T.; Roberts, S. M.; Shoberu, K. A.; Sutherland, A. G. J. Chem. Soc. Perkin Trans 1 **1992**, 589.
- (a) Waga, T.; Ohriu, H.; Meguro, H. Nucleosides & Nucleotides 1996, 15, 287; (b) Waga, T.; Nishizaki, T.; Miyakawa, J.; Ohriu, H.; Meguro, H. Biosci. Biotechnol. Biochem. 1993, 57, 1433.
- Kato, K.; Suzuki, H.; Tanaka, H.; Miyasaka, T.; Baba, M.; Yamaguchi, K.; Akita, H. *Chem. Pharm. Bull.* **1999**, *47*, 1256.
- (a) Haines, D. R.; Tseng, C. K. H.; Marquez, V. E. J. Med. Chem. 1987, 30, 943; (b) Jeong, L. S.; Lee, Y. A.; Moon, H. R.; Chun, M. W. Nucleosides & Nucleotides 1998, 17, 1473.
- (a) Hossain, N.; Rozenski, J.; De Clercq, E.; Herdewjn, P. *Tetrahedron* 1996, *52*, 13655; (b) Jeon, G. S.; Nair, V. *Tetrahedron* 1996, *52*, 12643.
- (a) Gundersen, L.-L.; Benneche, T.; Undheim, K. *Tetrahedron Lett.* **1992**, *33*, 1085; (b) Gundersen, L.-L.; Benneche, T.; Rise, F.; Gogoll, A.; Undheim, K. *Acta Chem. Scand.* **1992**, *46*, 761.